

(19) **DANMARK**

(10) **DK/EP 2803663 T3**



Patent- og
Varemærkestyrelsen

(12) Oversættelse af
europæisk patentskrift

-
- (51) Int.Cl.: *C 07 D 277/28 (2006.01)* *A 61 K 31/425 (2006.01)* *A 61 P 7/10 (2006.01)*
A 61 P 35/00 (2006.01) *C 07 D 417/04 (2006.01)* *C 07 D 417/12 (2006.01)*
C 07 D 417/14 (2006.01)
- (45) Oversættelsen bekendtgjort den: **2018-03-05**
- (80) Dato for Den Europæiske Patentmyndigheds
bekendtgørelse om meddelelse af patentet: **2017-11-29**
- (86) Europæisk ansøgning nr.: **14166121.5**
- (86) Europæisk indleveringsdag: **2007-06-27**
- (87) Den europæiske ansøgnings publiceringsdag: **2014-11-19**
- (30) Prioritet: **2006-06-27 US 816825 P**
- (62) Stamansøgningsnr: **07809909.0**
- (84) Designerede stater: **AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT
NL PL PT RO SE SI SK TR**
- (73) Patenthaver: **Aerpio Therapeutics, Inc., 9987 Carver Road, Suite 420, Cincinnati, OH 45242, USA**
- (72) Opfinder: **Gray, Jeffrey Lyle, 11313 Enyarat Road, Loveland, OH Ohio 45140, USA**
Clark, Cynthia, Monesa, 30 Kenney Lane, Concord, MA Massachusetts 01742, USA
Amarasinghe, Kande, 3025 Katherine Place, Ellicott City, MD 21042, USA
Maier, Mathew, Brian, 15 Naim Ct, Springboro, OH Ohio 45066, USA
Nichols, Ryan, 2122 Varelman Ave, Cincinnati, OH Ohio 45212, USA
- (74) Fuldmægtig i Danmark: **Plougmann Vingtoft A/S, Rued Langgaards Vej 8, 2300 København S, Danmark**
- (54) Benævnelse: **Human protein tyrosin-phosphatase-inhibitorer og deres farmaceutiske anvendelse**
- (56) Fremdragne publikationer:
EP-A2- 0 701 817
US-A- 5 866 570
US-A1- 2004 167 183
US-A1- 2004 242 676
US-A1- 2005 282 814

DESCRIPTION

FIELD

[0001] The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP- β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising one or more human protein tyrosine phosphatase beta (HPTP- β) inhibitors, and to methods for regulating angiogenesis. In particular the present disclosure relates to compounds for use in treating vascular leakage syndrome.

BACKGROUND

[0002] Angiogenesis, the sprouting of new blood vessels from the pre-existing vasculature, plays a crucial role in a wide range of physiological and pathological processes (Nguyen, L.L. et al., *Int. Rev. Cytol.*, 204, 1-48, (2001)). Angiogenesis is a complex process, mediated by communication between the endothelial cells that line blood vessels and their surrounding environment. In the early stages of angiogenesis, tissue or tumor cells produce and secrete pro-angiogenic growth factors in response to environmental stimuli such as hypoxia. These factors diffuse to nearby endothelial cells and stimulate receptors that lead to the production and secretion of proteases that degrade the surrounding extracellular matrix. The activated endothelial cells begin to migrate and proliferate into the surrounding tissue toward the source of these growth factors (Bussolino, F., *Trends Biochem. Sci.*, 22, 251-256, (1997)). Endothelial cells then stop proliferating and differentiate into tubular structures, which is the first step in the formation of stable, mature blood vessels. Subsequently, periendothelial cells, such as pericytes and smooth muscle cells, are recruited to the newly formed vessel in a further step toward vessel maturation.

[0003] Angiogenesis is regulated by a balance of naturally occurring pro- and anti-angiogenic factors. Vascular endothelial growth factor, fibroblast growth factor, and angiopoietin represent a few of the many potential pro-angiogenic growth factors. These ligands bind to their respective receptor tyrosine kinases on the endothelial cell surface and transduce signals that promote cell migration and proliferation. Whereas many regulatory factors have been identified, the molecular mechanisms of this process are still not fully understood.

[0004] There are many disease states driven by persistent unregulated or improperly regulated angiogenesis. In such disease states, unregulated or improperly regulated angiogenesis may either cause a particular disease or exacerbate an existing pathological condition. For example, ocular neovascularization has been implicated as the most common cause of blindness and underlies the pathology of approximately 20 eye diseases. In certain previously existing conditions such as arthritis, newly formed capillary blood vessels invade the joints and destroy cartilage. In diabetes, new capillaries formed in the retina invade the vitreous

humor, causing bleeding and blindness. Both the growth and metastasis of solid tumors are also angiogenesis-dependent (Folkman et al., "Tumor Angiogenesis," Chapter 10, 206-32, in *The Molecular Basis of Cancer*, Mendelsohn et al., eds., W. B. Saunders, (1995)). It has been shown that tumors which enlarge to greater than 2 mm in diameter must obtain their own blood supply and do so by inducing the growth of new capillary blood vessels. After these new blood vessels become embedded in the tumor, they provide nutrients and growth factors essential for tumor growth as well as a means for tumor cells to enter the circulation and metastasize to distant sites, such as liver, lung or bone (Weidner, *New Eng. J. Med.*, 324, 1, 1-8 (1991)). When used as drugs in tumor-bearing animals, natural inhibitors of angiogenesis may prevent the growth of small tumors (O'Reilly et al., *Cell*, 79, 315-28 (1994)). In some protocols, the application of such inhibitors leads to tumor regression and dormancy even after cessation of treatment (O'Reilly et al., *Cell*, 88, 277-85 (1997)). Moreover, supplying inhibitors of angiogenesis to certain tumors may potentiate their response to other therapeutic regimens (Teischer et al., *Int. J. Cancer*, 57, 920-25 (1994)).

[0005] Although many disease states are driven by persistent unregulated or improperly regulated angiogenesis, some disease states could be treated by increased angiogenesis. Tissue growth and repair are biologic events wherein cellular proliferation and angiogenesis occur. Thus an important aspect of wound repair is the revascularization of damaged tissue by angiogenesis.

[0006] Chronic, non-healing wounds are a major cause of prolonged morbidity in the aged human population. This is especially the case in bedridden or diabetic patients who develop severe, non-healing skin ulcers. In many of these cases, the delay in healing is a result of inadequate blood supply either as a result of continuous pressure or of vascular blockage. Poor capillary circulation due to small artery atherosclerosis or venous stasis contributes to the failure to repair damaged tissue. Such tissues are often infected with microorganisms that proliferate unchallenged by the innate defense systems of the body which require well vascularized tissue to effectively eliminate pathogenic organisms. As a result, most therapeutic intervention centers on restoring blood flow to ischemic tissues thereby allowing nutrients and immunological factors access to the site of the wound.

[0007] Atherosclerotic lesions in large vessels may cause tissue ischemia that could be ameliorated by modulating blood vessel growth to the affected tissue. For example, atherosclerotic lesions in the coronary arteries may cause angina and myocardial infarction that could be prevented if one could restore blood flow by stimulating the growth of collateral arteries. Similarly, atherosclerotic lesions in the large arteries that supply the legs may cause ischemia in the skeletal muscle that limits mobility and in some cases necessitates amputation, which may also be prevented by improving blood flow with angiogenic therapy.

[0008] Other diseases such as diabetes (US 2004/0167183) and hypertension are characterized by a decrease in the number and density of small blood vessels such as arterioles and capillaries. These small blood vessels are important for the delivery of oxygen and nutrients. A decrease in the number and density of these vessels contributes to the

adverse consequences of hypertension and diabetes including claudication, ischemic ulcers, accelerated hypertension, and renal failure. These common disorders and many other less common ailments, such as Burgers disease, could be ameliorated by increasing the number and density of small blood vessels using angiogenic therapy.

[0009] It has been suggested that one means for regulating angiogenesis is to treat patients with a human protein tyrosine phosphatase beta (HPTP- β) inhibitor (Kruegar et al., EMBO J., 9, (1990)) and, therefore, to satisfy this need the compounds of the present disclosure have been prepared.

SUMMARY OF THE DISCLOSURE

[0010] The compounds of the present disclosure are a new class of compounds that can regulate angiogenesis in humans.

[0011] The present disclosure further relates to pharmaceutical compositions and their pharmaceutically acceptable salts, and/or pharmaceutical compositions thereof comprising

1. a) an effective amount of one or more compounds according to the present disclosure;
and
2. b) an excipient..

[0012] The present disclosures also relate to methods for controlling angiogenesis, and thereby providing a treatment for diseases affected by angiogenesis, said methods comprising administering to a human an effective amount of a compound according to the present disclosure. These and other objects, features, and advantages will become apparent to those of ordinary skill in the art from a reading of the following detailed description and the appended claims. All percentages, ratios and proportions herein are by weight, unless otherwise specified. All temperatures are in degrees Celsius ($^{\circ}\text{C}$) unless otherwise specified. All documents cited are in relevant part, incorporated herein by reference; the citation of any document is not to be construed as an admission that it is prior art with respect to the present disclosure.

DETAILED DESCRIPTION OF THE DISCLOSURE

[0013] In this specification and in the claims that follow, reference will be made to a number of terms, which shall be defined to have the following meanings:

By "pharmaceutically acceptable" is meant a material that is not biologically or otherwise undesirable, i.e., the material can be administered to an individual along with the relevant

active compound without causing clinically unacceptable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.

[0014] Throughout the description and claims of this specification the word "comprise" and other forms of the word, such as "comprising" and "comprises," means including and is not intended to exclude, for example, other additives, components, integers, or steps.

[0015] As used in the description and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a composition" includes mixtures of two or more such compositions.

[0016] "Optional" or "optionally" means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

[0017] Ranges can be expressed herein as from "about" one particular value, and/or to "about" another particular value. When such a range is expressed, another aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about," it will be understood that the particular value forms another aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as "about" that particular value in addition to the value itself. For example, if the value "10" is disclosed, then "about 10" is also disclosed. It is also understood that when a value is disclosed, then "less than or equal to" the value, "greater than or equal to the value," and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value "10" is disclosed, then "less than or equal to 10" as well as "greater than or equal to 10" is also disclosed. It is also understood that throughout the application data are provided in a number of different formats and that this data represent endpoints and starting points and ranges for any combination of the data points. For example, if a particular data point "10" and a particular data point "15" are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.

[0018] The term "organic unit" as described herein refers to groups or moieties that comprise one or more carbon atoms and which form a portion of one of the compounds or pharmaceutically acceptable salts thereof. For example, many of the substituent units referred to elsewhere herein are organic units. In order to effectively function in the context of their presence in the compounds and/or salts disclosed herein, the organic units should often have

variable ranges of restricted size and/or molecular weight, so as to provide desired binding to the target enzymes, solubility, bioabsorption characteristics. For example, organic unit can have, for example, 1-26 carbon atoms, 1-18 carbon atoms, 1-12 carbon atoms, 1-8 carbon atoms, or 1-4 carbon atoms. Organic units often have hydrogen bound to at least some of the carbon atoms of the organic units, and can optionally contain the common heteroatoms found in substituted organic compounds, such as oxygen, nitrogen, sulfur, or inorganic atoms such as halogens, phosphorus. One example, of an organic radical that comprises no inorganic atoms is a 5, 6, 7, 8-tetrahydro-2-naphthyl radical. In some embodiments, an organic radical can contain 1-10 inorganic heteroatoms bound thereto or therein, including halogens, oxygen, sulfur, nitrogen, phosphorus. Examples of organic radicals include an alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, mono-substituted amino, di-substituted amino, acyloxy, cyano, carboxy, carboalkoxy, alkylcarboxamido, substituted alkylcarboxamido, dialkylcarboxamido, substituted dialkylcarboxamido, alkylsulfonyl, alkylsulfinyl, thioalkyl, thiohaloalkyl, alkoxy, substituted alkoxy, haloalkyl, haloalkoxy, aryl, substituted aryl, heteroaryl, heterocyclic, or substituted heterocyclic radicals, wherein the terms are defined elsewhere herein. A few examples of organic radicals that include heteroatoms include alkoxy radicals, trifluoromethoxy radicals, acetoxy radicals, and dimethylamino radicals.

[0019] Substituted and unsubstituted linear, branched, or cyclic alkyl units include the following examples: methyl (C₁), ethyl (C₂), n-propyl (C₃), *iso*-propyl (C₃), cyclopropyl (C₃), n-butyl (C₄), *sec*-butyl (C₄), *iso*-butyl (C₄), *tert*-butyl (C₄), cyclobutyl (C₄), cyclopentyl (C₅), cyclohexyl (C₆); whereas substituted linear, branched, or cyclic alkyl, examples of which includes, hydroxymethyl (C₁), chloromethyl (C₁), trifluoromethyl (C₁), aminomethyl (C₁), 1-chloroethyl (C₂), 2-hydroxyethyl (C₂), 1,2-difluoroethyl (C₂), 2,2,2-trifluoroethyl (C₃), 3-carboxypropyl (C₃), 2,3-dihydroxycyclobutyl (C₄).

[0020] Substituted and unsubstituted linear, branched, or cyclic alkenyl include, ethenyl (C₂), 3-propenyl (C₃), 1-propenyl (*also* 2-methylethenyl) (C₃), isopropenyl (*also* 2-methylethen-2-yl) (C₃), buten-4-yl (C₄), and the like; substituted linear or branched alkenyl, examples of which include, 2-chloroethenyl (*also* 2-chlorovinyl) (C₂), 4-hydroxybuten-1-yl (C₄), 7-hydroxy-7-methyloct-4-en-2-yl (C₉), 7-hydroxy-7-methyloct-3,5-dien-2-yl (C₉).

[0021] Substituted and unsubstituted linear or branched alkynyl include, ethynyl (C₂), prop-2-ynyl (*also* propargyl) (C₃), propyn-1-yl (C₃), and 2-methyl-hex-4-yn-1-yl (C₇); substituted linear or branched alkynyl, examples of which include, 5-hydroxy-5-methylhex-3-ynyl (C₇), 6-hydroxy-6-methylhept-3-yn-2-yl (C₈), 5-hydroxy-5-ethylhept-3-ynyl (C₉).

[0022] Substituted and unsubstituted "alkoxy" are used herein denotes a unit having the general formula -OR¹⁰⁰ wherein R¹⁰⁰ is an alkyl, alkylenyl, or alkynyl unit as defined herein above, for example, methoxy, methoxymethyl, methoxymethyl.


[0023] Substituted and unsubstituted "haloalkyl" are used herein denotes an alkyl unit having

a hydrogen atom substituted by one or more halogen atoms, for example, trifluoromethyl, 1,2-dichloroethyl, and 3,3,3-trifluoropropyl.


[0024] The term "aryl" as used herein denotes cyclic organic units that comprise at least one benzene ring having a conjugated and aromatic six-membered ring, examples of which include phenyl (C₆), naphthyl-1-yl (C₁₀), naphthyl-2-yl (C₁₀). Aryl rings can have one or more hydrogen atoms substituted by another organic or inorganic radical. Examples of substituted aryl rings include: 4-fluorophenyl (C₆), 2-hydroxyphenyl (C₆), 3-methylphenyl (C₆), 2-amino-4-fluorophenyl (C₆), 2-(*N,N* diethylamino)phenyl (C₆), 2-cyanophenyl (C₆), 2,6-di-*tert*-butylphenyl (C₆), 3-methoxyphenyl (C₆), 8-hydroxynaphthyl-2-yl (C₁₀), 4,5-dimethoxynaphthyl-1-yl (C₁₀), and 6-cyanonaphthyl-1-yl (C₁₀).

[0025] The term "heteroaryl" denotes an organic unit comprising a five or six member conjugated and aromatic ring wherein at least one of the ring atoms is a heteroatom selected from nitrogen, oxygen, or sulfur. The heteroaryl rings can comprise a single ring, for example, a ring having 5 or 6 atoms wherein at least one ring atom is a heteroatom nitrogen, oxygen, or sulfur, such as a pyridine ring, a furan ring, or thiofuran ring. A "heteroaryl" can also be a fused multicyclic and heteroaromatic ring system having wherein at least one of the rings is an aromatic ring and at least one atom of the aromatic ring is a heteroatom including nitrogen, oxygen, or sulfur

[0026] The following are examples of heteroaryl rings according to the present disclosure:




[0027] The term "heterocyclic" denotes a ring system having from 3 to 10 atoms wherein at least one of the ring atoms is a heteroatom nitrogen, oxygen, or sulfur. The rings can be single rings, fused rings, or bicyclic rings. Examples of heterocyclic rings include:



[0028] All of the aforementioned heteroaryl or heterocyclic rings can be optionally substituted with one or more substitutes for hydrogen as described herein further.

[0029] Throughout the description of the present disclosure the terms having the spelling "thiophene-2-yl and thiophene-3-yl" are used to describe the heteroaryl units having the respective formulae:



whereas in naming the compounds of the present disclosure, the chemical nomenclature for

these moieties are typically spelled "thiophen-2-yl and thiophen-3-yl" respectively. Herein the terms "thiophene-2-yl and thiophene-3-yl" are used when describing these rings as units or moieties which make up the compounds of the present disclosure solely to make it unambiguous to the artisan of ordinary skill which rings are referred to herein.

[0030] The following are examples of units that can substitute for hydrogen atoms:

i) C_1 - C_{12} linear, branched, or cyclic alkyl, alkenyl, and alkynyl; for example, methyl (C_1), ethyl (C_2), ethenyl (C_2), ethynyl (C_2), n-propyl (C_3), *iso*-propyl (C_3), cyclopropyl (C_3), 3-propenyl (C_3), 1-propenyl (*also* 2-methylethenyl) (C_3), isopropenyl (*also* 2-methylethen-2-yl) (C_3), prop-2-ynyl (*also* propargyl) (C_3), propyn-1-yl (C_3), n-butyl (C_4), *sec*-butyl (C_4), *iso*-butyl (C_4), *tert*-butyl (C_4), cyclobutyl (C_4), buten-4-yl (C_4), cyclopentyl (C_5), cyclohexyl (C_6);

ii) substituted or unsubstituted C_6 or C_{10} aryl; for example, phenyl, naphthyl (also referred to herein as naphthylen-1-yl (C_{10}) or naphthylen-2-yl (C_{10}));

iii) substituted or unsubstituted C_1 - C_9 heterocyclic rings; as described herein below;

iv) substituted or unsubstituted C_1 - C_9 heteroaryl rings; as described herein below;

v) $-(CR^{12a}R^{12b})_zOR^{11}$; for example, -OH, -CH₂OH, -OCH₃, -CH₂OCH₃, -OCH₂CH₃, -CH₂OCH₂CH₃, -OCH₂CH₂CH₃, and -CH₂OCH₂CH₂CH₃;

vi) $-(CR^{12a}R^{12b})_zC(O)R^{11}$; for example, -COCH₃, -CH₂COCH₃, -OCH₂CH₃, -CH₂COCH₂CH₃, -COCH₂CH₂CH₃, and -CH₂COCH₂CH₂CH₃;

vii) $-(CR^{12a}R^{12b})_zC(O)OR^{11}$; for example, -CO₂CH₃, -CH₂CO₂CH₃, -CO₂CH₂CH₃, -CH₂CO₂CH₂CH₃, -CO₂CH₂CH₂CH₃, and -CH₂CO₂CH₂CH₂CH₃;

viii) $-(CR^{12a}R^{12b})_zC(O)N(R^{11})_2$; for example, -CONH₂, -CH₂CONH₂, -CONHCH₃, -CH₂CONHCH₃, -CON(CH₃)₂, and -CH₂CON(CH₃)₂;

ix) $-(CR^{12a}R^{12b})_zN(R^{11})_2$; ; for example, -NH₂, -CH₂NH₂, -NHCH₃, -N(CH₃)₂, -NH(CH₂CH₃), -CH₂NHCH₃, -CH₂N(CH₃)₂, and -CH₂NH(CH₂CH₃);

x) halogen; -F, -Cl, -Br, and -I;

xi) $-(CR^{12a}R^{12b})_zCN$;

xii) $-(CR^{12a}R^{12b})_zNO_2$;

xiii) -CH_jX_k; wherein X is halogen, j is from 0 to 2, j + k = 3; for example, -CH₂F, -CHF₂, -CF₃, -CCl₃, or -CBr₃;

xiv) $-(\text{CR}^{12a}\text{R}^{12b})_z\text{SR}^{11}$; -SH, -CH₂SH, -SCH₃, -CH₂SCH₃, -SC₆H₅, and -CH₂SC₆H₅;

xv) $-(\text{CR}^{12a}\text{R}^{12b})_z\text{SO}_2\text{R}^{11}$; -SO₂H, -CH₂SO₂H, -SO₂CH₃, -CH₂SO₂CH₃, -SO₂C₆H₅, and -CH₂SO₂C₆H₅; and

xiii) $-(\text{CR}^{12a}\text{R}^{12b})_z\text{SO}_3\text{R}^{11}$; for example, -SO₃H, -CH₂SO₃H, -SO₃CH₃, -CH₂SO₃CH₃, -SO₃C₆H₅, and -CH₂SO₃C₆H₅;

wherein each R¹³ is independently hydrogen, substituted or unsubstituted C₁-C₄ linear, branched, or cyclic alkyl, phenyl, benzyl; or two R¹³ units can be taken together to form a ring comprising 3-7 atoms; R^{14a} and R^{14b} are each independently hydrogen or C₁-C₄ linear or branched alkyl; the index p is from 0 to 4.

[0031] For the purposes of the present disclosure the terms "compound," "analog," and "composition of matter" stand equally well for the phenylsulfamic acids described herein, including all enantiomeric forms, diastereomeric forms, and salts, and the terms "compound," "analog," and "composition of matter" are used interchangeably throughout the present specification.

[0032] The present disclosure addresses a major unmet medical need, *inter alia*; providing compositions of effective human protein tyrosine phosphatase beta (HPTP-β) inhibitors; and thereby provide a means for regulating angiogenesis and blood vessel remodeling in disorders wherein angiogenesis is decreased or where tissue blood flow is insufficient or where increased blood flow would be beneficial.

[0033] This and other unmet medical needs are resolved by the human protein tyrosine phosphatase beta (HPTP-β) inhibitors of the present disclosure, which are capable of regulating angiogenesis and blood vessel remodeling and thereby serve as a means for treating diseases which are caused by insufficient regulation of human protein tyrosine phosphatase beta (HPTP-β).


[0034] The compounds disclosed herein include all pharmaceutically acceptable salt forms, for example, salts of both basic groups, *inter alia*, amines, as well as salts of acidic groups, *inter alia*, sulfamic acids, and carboxylic acids. The following are examples of anions that can form salts with basic groups: chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, and citrate, . The following are examples of cations that can form salts of acidic groups: sodium, lithium, potassium, calcium, magnesium, and bismuth, .

R Units

[0035] R is a unit chosen from:


1. i) hydrogen;
2. ii) substituted or unsubstituted phenyl; and
3. iii) substituted or unsubstituted heteroaryl ring.

[0036] One example of R relates to compounds wherein R is hydrogen, said compounds having the general formula:



wherein Z is further defined herein below.

[0037] Another example of the compounds of Formula (I) includes compounds wherein R is phenyl or substituted phenyl, said compounds having the general formula:




wherein R¹⁰ represents one or more optional replacements for hydrogen, as defined in claim 1.


[0038] Another example of the compounds of Formula (I) includes compounds wherein R is a substituted or unsubstituted heteroaryl ring. For the purposes of the present disclosure the following are examples of heteroaryl rings suitable as R units for the compounds of the present disclosure: 1,2,3,4-tetrazolyl; [1,2,3]triazolyl; imidazolyl; pyrrolyl; oxazolyl; isoxazolyl; [1,2,4]oxadiazolyl; [1,3,4]oxadiazolyl; furanyl; thiophenyl; isothiazolyl; thiazolyl; [1,2,4]thiadiazolyl; and [1,3,4]thiadiazolyl.

[0039] The heteroaryl units that comprise R units can be substituted by one or more units chosen from methyl, ethyl, n-propyl, *iso*-propyl, cyclopropyl, n-butyl, *sec*-butyl, *iso*-butyl, *tert*-butyl, cyclopropylmethyl, methoxy, ethoxy, n-propoxy, *iso*-propoxy, cyclopropoxy, n-butoxy, *sec*-butoxy, *iso*-butoxy, *tert*-butoxy, cyclopropoxy, fluoro, chloro, fluoromethyl, difluoromethyl, and trifluoromethyl.


[0040] An example of the compounds of Formula (I) includes compounds wherein R units include units having the formulae:




[0041] Another example of the compounds of Formula (I) includes compounds wherein R units include units having the formulae:



[0042] A further example of the compounds of Formula (I) includes compounds wherein R units include units having the formulae:



[0043] Z is a substituted or unsubstituted [1,3,4]thiadiazol-2-yl unit having the formula:




and R^1 is a substituent group that can be independently chosen from a wide variety of inorganic (hydrogen, hydroxyl, amino, halogen or the like) or organic substituent units, such as alkyls, cycloalkyls, heterocyclic, and heteroaryl, wherein such substituent units can optionally have from 1 to 12 carbon atoms, or 1 to 10 carbon atoms, or 1 to six carbon atoms. In many aspects of the invention R^1 is chosen from:

- i) hydrogen;
- ii) substituted or unsubstituted C_1 - C_6 linear, branched, or cyclic alkyl as defined in claim 1;
- iii) substituted or unsubstituted C_6 or C_{10} aryl as defined in claim 1;
- iv) $-OR^4$;
- v) $-C(O)OR^5$;
- vi) $-COR^6$; and
- vii) $-NR^7C(O)OR^8$;

R^4 is hydrogen or substituted or unsubstituted C_1 - C_6 linear, branched, or cyclic alkyl; R^5 is C_1 - C_6 linear or branched alkyl, or benzyl; R^6 is C_1 - C_6 linear, branched, or cyclic alkyl, or phenyl; R^7 is hydrogen or methyl; R^8 is C_1 - C_6 linear or branched alkyl, or benzyl.

[0044] One example of compounds according to Formula (I) includes an R^1 unit that is hydrogen thereby providing compounds having the general formula:



wherein R is defined herein above.

[0045] Another example of compounds according to Formula (I) includes compounds wherein R^1 is substituted or unsubstituted C_1 - C_6 linear, branched, or cyclic alkyl, examples of which include R^1 units chosen from methyl, ethyl, n-propyl, *iso*-propyl, cyclopropyl, n-butyl, *sec*-butyl, *iso*-butyl, *tert*-butyl, and cyclopropylmethyl.

[0046] A further example of compounds according to Formula (I) includes compounds wherein R^1 is a substituted or unsubstituted C_6 or C_{10} aryl unit, i.e. phenyl, naphthylen-1-yl, and naphthylen-2-yl. Examples of this aspect include phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-ethylphenyl, 3-ethylphenyl, 4-ethylphenyl, 2-isopropylphenyl, 3-isopropylphenyl, 4-isopropylphenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 2-nitrophenyl, 3-nitrophenyl, 4-nitrophenyl, 2-aminophenyl, 2-(*N*-methylamino)phenyl, 2-(*N,N*-dimethylamino)phenyl, 2-(*N*-ethylamino)phenyl, 2-(*N,N*-diethylamino)phenyl, 3-aminophenyl, 3-(*N*-methylamino)phenyl, 3-(*N,N*-dimethylamino)phenyl, 3-(*N*-ethylamino)phenyl, 3-(*N,N*-diethylamino)phenyl, 4-aminophenyl, 4-(*N*-methylamino)phenyl, 4-(*N,N*-dimethylamino)phenyl, 4-(*N*-ethylamino)phenyl, 4-(*N,N*-diethylamino)phenyl, naphthylen-1-yl, and naphthylen-2-yl

[0047] A yet further example of compounds according to Formula (I) includes compounds wherein R^1 has the formula $-NR^7C(O)OR^8$; R^7 is hydrogen and R^8 is chosen from methyl (C_1), ethyl (C_2), n-propyl (C_3), *iso*-propyl (C_3), and cyclopropyl (C_3).

[0048] The Z units of the present disclosure can further comprise a linking unit L, which when present, serves to connect the [1,3,4]thiadiazol-2-yl unit to the R^1 unit. When the index x is equal to 0, the linking unit is absent. When the index x is equal to 1 the linking unit is present.

[0049] L is a linking unit having the formula:




wherein R^{9a} and R^{9b} are each independently hydrogen, C_1 - C_6 linear or branched alkyl, or phenyl and the index y is from 1 to 4.

[0050] One example of L units includes units wherein R^{9a} and R^{9b} are each hydrogen and the index y is equal to 1, these units have the formula:




that is also referred to herein as methylene linking units.

[0051] Another example of L units includes units wherein all R^{9a} and R^{9b} units are hydrogen and the index y is equal to 2, this unit has the formula:




and is also referred to herein as an ethylene linking unit.


[0052] As described herein above the compounds of the present invention includes all pharmaceutically acceptable salt forms. A compound having the formula:




can form salts, for example, a salt of the sulfonic acid:




and



The compounds can also exist in a zwitterionic form, for example:





or as a salt of a strong acid, for example:



[0053] The analogs (compounds) of the present disclosure are arranged into several categories to assist the formulator in applying a rational synthetic strategy for the preparation of analogs which are not expressly exemplified herein. The arrangement into categories does not imply increased or decreased efficacy for any of the compositions of matter described herein.


[0054] The compounds of the present disclosure can be prepared using the procedure outlined herein below in steps (a) - (f) or by making modifications thereof which are known to those skilled in the art and by which can be accomplished without the need for undue experimentation.





[0055] Scheme I herein below outlines the procedure for preparing the analogs of the present disclosure that is described in detail in Example 1.


Scheme I



1

[0056] Reagents and conditions: (a)(i) (*iso*-butyl)OCOCl, Et_3N , THF; 0 °C, 20 min.


(ii) CH_2N_2 ; 0 °C to room temp for 3 hours.



1

2


[0057] Reagents and conditions: (b) 48% HBr, THF; 0 °C, 1.5 hr.



2

3


[0058] Reagents and conditions: (c) CH_3CN ; reflux 2hr.



3


4

[0059] Reagents and conditions: (d) thiophosgene, CaCO_3 , CCl_4 , H_2O ; rt, 18 hr.



[0060] Reagents and conditions: (e)(i) $\text{CH}_3\text{C}(\text{O})\text{NHNH}_2$, EtOH; reflux, 2 hr.

(ii) POCl_3 , rt 18 hr; 50 °C 2 hr.



[0061] Reagents and conditions: (f) (i) H_2 :Pd/C, MeOH; (ii) SO_3 -pyridine, NH_4OH .

EXAMPLE 1

(S)-4-(2-(5-methyl-1,3,4-thiadiazol-2-ylamino)-2-(2-phenylthiazol-4-yl)ethyl)phenylsulfamic acid (6)

[0062] Preparation of [3-diazo-1-(4-nitrobenzyl)-2-oxo-propyl]-carbamic acid *tert*-butyl ester (1): To a 0 °C solution of 2-(*S*)-*tert*-butoxycarbonylamino-3-(4-nitrophenyl)-propionic acid (1.20 g, 4.0 mmol) in THF (20 mL) is added dropwise triethylamine (0.61 mL, 4.4 mmol) followed by *iso*-butyl chloroformate (0.57 mL, 4.4 mmol). The reaction mixture is stirred at 0 °C for 20 min and filtered. The filtrate is treated with an ether solution of diazomethane (~16 mmol) at 0 °C. The reaction mixture is stirred at room temperature for 3 hours and concentrated. The residue is dissolved in EtOAc and washed successively with water and brine, dried (Na_2SO_4), filtered and concentrated in vacuo. The resulting residue is purified over silica (hexane/EtOAc 2:1) to afford 1.1 g (82% yield) of the desired product as a slightly yellow solid. ^1H NMR (300 MHz, CDCl_3) δ 8.16 (d, J = 8.7 Hz, 2H), 7.39 (d, J = 8.7 Hz, 2H), 5.39 (s, 1H), 5.16 (d, J = 6.3 Hz, 1H), 4.49 (s, 1H), 3.25 (dd, J = 13.8 and 6.6, 1H), 3.06 (dd, J = 13.5 and 6.9 Hz, 1H), 1.41 (s,

9H).

[0063] Preparation of [3-bromo-1-(4-nitro-benzyl)-2-oxo-propyl]-carbamic acid *tert*-butyl ester (2): To a 0 °C solution of [3-diazo-1-(4-nitrobenzyl)-2-oxo-propyl]-carbamic acid *tert*-butyl ester, 1, (0.350 g, 1.04 mmol) in THF (5 mL) is added dropwise 48% aq. HBr (0.14 mL, 1.25 mmol). The reaction mixture is stirred at 0 °C for 1.5 hours and quenched at 0 °C with sat. Na₂CO₃. The mixture is extracted with EtOAc (3x 25 mL) and the combined organic extracts are washed with brine, dried (Na₂SO₄), filtered and concentrated in vacuo to afford 0.400 g of the desired product which is used in the next step without further purification. ¹H NMR (300 MHz, CDCl₃) δ 8.20 (d, *J* = 8.4 Hz, 2H), 7.39 (d, *J* = 8.4 Hz, 2H), 5.06 (d, *J* = 7.8 Hz, 1H), 4.80 (q, *J* = 6.3 Hz, 1H), 4.04 (s, 2H), 1.42 (s, 9H).

[0064] Preparation of (S)-2-(4-nitrophenyl)-1-(2-phenylthiazol-4-yl)ethanamine hydrobromide salt (3): A mixture of [3-bromo-1-(4-nitro-benzyl)-2-oxo-propyl]-carbamic acid -*tert*-butyl ester, 2, (1.62 g, 4.17 mmol) and benzothioamide (0.630 g, 4.59 mmol), in CH₃CN (5 mL) is refluxed for 24 hours. The reaction mixture is cooled to room temperature and diethyl ether (50 mL) is added to the solution and the precipitate which forms is collected by filtration. The solid is dried under vacuum to afford 1.059 g (63%) of the desired product. ESI+MS 326 (M+1).

[0065] Preparation of (S)-4-(1-isothiocyanato-2-(4-nitrophenyl)ethyl)-2-phenylthiazole (4): To a solution of (S)-2-(4-nitrophenyl)-1-(2-phenylthiazol-4-yl)ethanamine hydrobromide salt, 3, (2.03g, 5 mmol) and CaCO₃ (1 g, 10 mmol) in CCl₄/water (10:7.5 mL) is added thiophosgene (0.46 mL, 6 mmol). The reaction is stirred at room temperature for 18 hours then diluted with CH₂Cl₂ and water. The layers are separated and the aqueous layer extracted with CH₂Cl₂. The combined organic layers are washed with brine, dried (Na₂SO₄) and concentrated *in vacuo* to a residue which is purified over silica (CH₂Cl₂) to afford 1.71g (93%) of the desired product. ESI+ MS 368 (M+1).

[0066] Preparation of (S)-5-methyl-*N*-(2-(4-nitrophenyl)-1-(2-phenylthiazol-4-yl)ethyl)-1,3,4-thiadiazol-2-amine (5): A solution of (S)-4-(1-isothiocyanato-2-(4-nitrophenyl)-ethyl)-2-phenylthiazole, 4, (332 mg, 0.876 mmol) and acetic hydrazide (65 mg, 0.876 mmol) in EtOH (5 mL) is refluxed for 2 hours. The solvent is removed under reduced pressure, the residue is dissolved in POCl₃ (3 mL) and the resulting solution is stirred at room temperature for 18 hours after which the solution is heated to 50 °C for 2 hours. The solvent is removed *in vacuo* and the residue is dissolved in EtOAc (40 mL) and the resulting solution is treated with 1N NaOH until the pH remains approximately 8. The solution is extracted with EtOAc. The combined aqueous layers are washed with EtOAc, the organic layers combined, washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo* to afford 0.345 g (93%) of the desired product as a yellow solid. ¹H NMR (CDCl₃) 8.09 (d, *J* = 8.4 Hz, 2H), 7.91 (m, 2H), 7.46 (m, 4H), 7.44 (s, 1H), 5.23 (m, 1H), 3.59 (m, 2H), 2.49 (s, 3H). ESI+ MS 424 (M+1).

[0067] Preparation of (S)-4-(2-(5-methyl-1,3,4-thiadiazol-2-ylamino)-2-(2-phenylthiazol-4-

yl)ethyl)phenylsulfamic acid (6): (S)-5-Methyl-N-(2-(4-nitrophenyl)-1-(2-phenylthiazol-4-yl)ethyl)-1,3,4-thiadiazol-2-amine, 5, (0.404 g, 0.954 mmol) is dissolved in MeOH (5 mL). Pd/C (50 mg, 10% w/w) is added and the mixture is stirred under a hydrogen atmosphere until the reaction is judged to be complete. The reaction mixture is filtered through a bed of CELITE™ and the solvent removed under reduced pressure. The crude product is dissolved in pyridine (4 mL) and treated with SO₃-pyridine (0.304 g, 1.91 mmol). The reaction is stirred at room temperature for 5 minutes after which a 7% solution of NH₄OH (50 mL) is added. The mixture is then concentrated and the resulting residue is purified by reverse phase preparative HPLC to afford 0.052 g (11% yield) of the desired product as the ammonium salt. ¹H (CD₃OD): δ 8.00-7.97 (m, 2H), 7.51-7.47 (m, 3H), 7.23 (s, 1H), 7.11-7.04 (q, 4H, J=9.0 Hz), 5.18 (t, 1H, J=7.2 Hz), 3.34-3.22 (m, 2H), 2.50 (s, 3H). ESI- MS 472 (M-1).

[0068] The following is a general procedure for isolating the final compound as a free acid.

[0069] Reduction of the aryl nitro group to free a amine:

To a Parr hydrogenation vessel is charged the nitro compound [for example, intermediate 5] (1.0 eq) and Pd/C (10 % Pd on C, 50 % wet, Degussa-type E101 NE/W, 2.68 g, 15 wt %) as solids. MeOH (15 mL/g) is added to provide a suspension. The vessel is put on a Parr hydrogenation apparatus. The vessel is submitted to a fill/vacuum evacuate process with N₂ (3 x 20 psi) to inert, followed by the same procedure with H₂ (3 x 40 psi). The vessel is filled with H₂ and the vessel is shaken under 40 psi H₂ for ~40 hr. The vessel is evacuated and the atmosphere is purged with N₂ (5 x 20 psi). An aliquot is filtered and analyzed by HPLC to insure complete conversion. The suspension is filtered through a pad of celite to remove the catalyst, and the homogeneous yellow filtrate is concentrated by rotary evaporation to afford the desired product which is used without further purification.

[0070] Preparation of free sulfamic acid: A 100 mL RBF is charged with the free amine (1.0 eq) prepared in the step described herein above. Acetonitrile (5 mL/g) is added and the yellow suspension which is typically yellow to orange in color is stirred at room temperature. A second 3-necked 500 mL RBF is charged with SO₃⁻ pyr (1.4 eq) and acetonitrile (5 mL/g) and the suspension is stirred at room temperature. Both suspensions are gently heated until the reaction solution containing the amine becomes orange to red-orange in color (typically at about 40-45 °C). This substrate containing solution is poured in one portion into the stirring suspension of SO₃⁻ pyr at 35 °C. The resulting opaque mixture is stirred vigorously while allowed to slowly cool to room temperature. After stirring for 45 min, or once the reaction is determined to be complete by HPLC, water (20 mL/g) is added to the colored suspension to provide a homogeneous solution having a pH of approximately 2.4. Concentrated H₃PO₄ is added slowly to lower the pH to approximately 1.4. During this pH adjustment, an off-white precipitate typically forms and the solution is stirred at room temperature for an additional hour. The suspension is filtered and the filter cake is washed with the filtrate. The filter cake is air-

dried overnight to afford the desired product as the free acid.

[0071] The following are examples of compounds according to the present disclosure.

(S)-4-(2-(5-Phenyl-1,3,4-thiadiazol-2-ylamino)-2-(2-phenylthiazol-4-yl)ethyl)-phenylsulfamic acid: ^1H (CD_3OD): δ 7.97-7.94 (m, 2H), 7.73-7.70 (m, 2H), 7.44-7.39 (m, 6H), 7.25 (s, 1H), 7.12 (s, 4H), 5.29 (t, 1H, $J=6.9$ Hz), 3.35-3.26 (m, 2H).

4-((S)-2-(5-Propyl-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenylsulfamic acid: ^1H (CD_3OD): δ 7.59-7.54 (m, 2H), 7.17-7.03 (m, 6H), 5.13 (t, 1H, $J=7.2$ Hz), 3.32-3.13 (m, 2H), 2.81 (t, 2H, $J=7.4$ Hz), 1.76-1.63 (h, 6H, $J=7.4$ Hz), 0.97 (t, 3H, $J=7.3$ Hz).

4-((S)-2-(5-Benzyl-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenylsulfamic acid: ^1H (CD_3OD): δ (m, 2H), 7.49-7.45 (m, 2H), 7.26-7.16 (m, 5H), 7.05-6.94 (m, 6H), 5.04 (t, 1H, $J=7.1$ Hz), 4.07 (s, 2H), 3.22-3.04 (m, 2H).

5-(3-Methoxybenzyl)-N-((S)-2-(4-nitrophenyl)-1-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)-1,3,4-thiadiazol-2-amine: ^1H (CD_3OD): δ 7.68-7.64 (m, 2H), 7.33 (t, 1H, $J=8.6$ Hz), 7.23-7.12 (m, 6H), 6.94-6.91 (m, 3H), 5.22 (t, 1H, $J=7.1$ Hz), 4.22 (s, 2H), 3.86 (s, 3H), 3.40-3.26 (m, 2H).

4-((S)-2-(5-(Naphthalen-1-ylmethyl)-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenylsulfamic acid: ^1H (CD_3OD): δ 8.08-8.05 (m, 1H), 7.89-7.80 (m, 2H), 7.55-7.43 (m, 6H), 7.11-7.00 (m, 6H), 5.08 (t, 1H, $J=7.1$ Hz), 4.63 (s, 2H), 3.26-3.08 (m, 2H).

4-((S)-2-(5-((Methoxycarbonyl)methyl)-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenylsulfamic acid: ^1H (CD_3OD): δ 7.48-7.44 (m, 2H), 7.03-6.92 (m, 6H), 5.02 (t, 1H, $J=7.2$ Hz), 4.30 (s, 2H), 3.55 (s, 3H), 3.22-3.02 (m, 2H).

4-((S)-2-(5-((2-Methylthiazol-4-yl)methyl)-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenylsulfamic acid: ^1H (CD_3OD): δ 7.60-7.56 (m, 2H), 7.19 (s, 1H), 7.15-7.12 (m, 2H), 7.09-7.03 (q, 4H, $J=8.7$ Hz), 5.14 (t, 1H, $J=7.2$ Hz), 4.28 (s, 2H), 3.33-3.14 (m, 2H), 2.67 (s, 3H).

[0072] Inhibition of HPTP- β provides a means for enhancing the activity of endothelial receptor tyrosine kinases including, angiopoietin receptor tyrosine kinase, Tie-2, and the VEGF receptor tyrosine kinase, VEGFR2, and thereby treat disease states wherein tissue blood flow is insufficient. The compounds of the present disclosure serve as a means for providing regulation of angiogenesis and other activities of endothelial receptor tyrosine kinases. As such the present disclosure addresses a major unmet medical need, *inter alia*;

[0073] Providing compositions of effective human protein tyrosine phosphatase beta (HPTP- β)

inhibitors; and thereby provide a means for regulating angiogenesis, blood vessel remodeling and other activities of endothelial receptor tyrosine kinases in disorders wherein where tissue blood flow is insufficient or where increased blood flow would be beneficial. The effect of human protein tyrosine phosphatase inhibitors has been shown to affect several human disease conditions or disorders, these disorders include ;

[0074] Vascular Leak Syndromes - Ardelt, A.A. et al., Stroke, 36, 337-341 (2005).
FORMULATIONS

[0075] The present disclosure also relates to compositions or formulations which comprise the HPTP β inhibitors according to the present disclosure. In general, the compositions of the present disclosure comprise:

1. a) an effective amount of one or more phenylsulfamic acids and salts thereof according to the present disclosure which are effective as human protein tyrosine phosphatase beta (HPTP- β) inhibitors; and
2. b) one or more excipients.

[0076] For the purposes of the present disclosure the term "excipient" and "carrier" are used interchangeably throughout the description of the present disclosure and said terms are defined herein as, "ingredients which are used in the practice of formulating a safe and effective pharmaceutical composition."

[0077] The formulator will understand that excipients are used primarily to serve in delivering a safe, stable, and functional pharmaceutical, serving not only as part of the overall vehicle for delivery but also as a means for achieving effective absorption by the recipient of the active ingredient. An excipient may fill a role as simple and direct as being an inert filler, or an excipient as used herein may be part of a pH stabilizing system or coating to insure delivery of the ingredients safely to the stomach. The formulator can also take advantage of the fact the compounds of the present disclosure have improved cellular potency, pharmacokinetic properties, as well as improved oral bioavailability.

[0078] Examples of compositions according to the present disclosure include:

1. a) from about 0.001 mg to about 1000 mg of one or more phenylsulfamic acids according to the present disclosure; and
2. b) one or more excipients.

[0079] Another embodiment according to the present disclosure relates to the following compositions:

1. a) from about 0.01 mg to about 100 mg of one or more phenylsulfamic acids according

- to the present disclosure; and
2. b) one or more excipients.

[0080] A further embodiment according to the present disclosure relates to the following compositions:

1. a) from about 0.1 mg to about 10 mg of one or more phenylsulfamic acids according to the present disclosure; and
2. b) one or more excipients.

[0081] The term "effective amount" as used herein means "an amount of one or more phenylsulfamic acids, effective at dosages and for periods of time necessary to achieve the desired or therapeutic result." An effective amount may vary according to factors known in the art, such as the disease state, age, sex, and weight of the human or animal being treated. Although particular dosage regimes may be described in examples herein, a person skilled in the art would appreciate that the dosage regime may be altered to provide optimum therapeutic response. Thus, it is not possible to specify an exact "effective amount." For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. In addition, the compositions of the present disclosure can be administered as frequently as necessary to achieve a therapeutic amount.

METHOD OF USE

[0082] The present disclosure relates to compounds as disclosed in claim 1 for use in treating vascular leakage syndrome.

PROCEDURES

Screening Assays using *in vitro* and *in vivo* models of angiogenesis

[0083] Compounds of the disclosure may be screened in angiogenesis assays that are known in the art. Such assays include *in vitro* assays that measure surrogates of blood vessel growth in cultured cells or formation of vascular structures from tissue explants and *in vivo* assays that measure blood vessel growth directly or indirectly (Auerbach, R., et al. (2003). Clin Chem 49, 32-40, Vailhe, B., et al. (2001). Lab Invest 81, 439-452).

1. *In vitro* models of angiogenesis

[0084] The *in vitro* models which are suitable for use in the present disclosure employ cultured endothelial cells or tissue explants and measure the effect of agents on "angiogenic" cell responses or on the formation of blood capillary-like structures. Examples of *in vitro* angiogenesis assays include endothelial cell migration and proliferation, capillary tube formation, endothelial sprouting, the aortic ring explant assay and the chick aortic arch assay.

2. *In vivo* models of angiogenesis

[0085] The *in vivo* agents or antibodies which are suitable for use in the present disclosure are administered locally or systemically in the presence or absence of growth factors (i.e. VEGF or angiopoietin 1) and new blood vessel growth is measured by direct observation or by measuring a surrogate marker such as hemoglobin content or a fluorescent indicator. Examples of *in vitro* angiogenesis assays include chick chorioallantoic membrane assay, the corneal angiogenesis assay, and the MATRIGEL™ plug assay.

3. Procedures for Determining Vascularization of Ischemic Tissue.

[0086] Standard routine techniques are available to determine if a tissue is at risk of suffering ischemic damage from undesirable vascular occlusion. For example, in myocardial disease these methods include a variety of imaging techniques (e.g., radiotracer methodologies, x-ray, and MRI) and physiological tests. Therefore, induction of angiogenesis as an effective means of preventing or attenuating ischemia in tissues affected by or at risk of being affected by a vascular occlusion can be readily determined.

[0087] A person skilled in the art of using standard techniques may measure the vascularization of tissue. Examples of measuring vascularization in a subject include SPECT (single photon emission computed tomography); PET (positron emission tomography); MRI (magnetic resonance imaging); and combination thereof, by measuring blood flow to tissue before and after treatment. Angiography may be used as an assessment of macroscopic vascularity. Histologic evaluation may be used to quantify vascularity at the small vessel level. These and other techniques are discussed in Simons, et al., "Clinical trials in coronary angiogenesis," *Circulation*, 102, 73-86 (2000).

[0088] The following are examples of HPTP β (IC₅₀ μ M) and PTP1B (IC₅₀ μ M) activity is listed herein below in Table I.

TABLE I

Compound	HPTP β IC ₅₀ μ M	PTP1B IC ₅₀ μ M
(S)-4-(2-(5-methyl-1,3,4-thiadiazol-2-ylamino)-2-(2-phenylthiazol-4-yl)ethyl)phenylsulfamic acid	0.003	1.4
(S)-4-(2-(5-Phenyl-1,3,4-thiadiazol-2-ylamino)-2-(2-phenylthiazol-4-yl)ethyl)-phenylsulfamic acid	0.046	3.7
4-((S)-2-(5-Propyl-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenylsulfamic acid	0.0002	4.71
4-((S)-2-(5-Benzyl-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenylsulfamic acid	0.0006	3.86
4-((S)-2-(5-((Methoxycarbonyl)methyl)-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenylsulfamic acid	0.002	1.55
4-((S)-2-(5-((2-Methylthiazol-4-yl)methyl)-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenylsulfamic acid	9×10^{-6}	0.58

[0089] While particular embodiments of the present disclosure have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the disclosure.

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [US20040167183A](#) **[0008]**


Non-patent literature cited in the description

- **NGUYEN, L.L. et al.** Int. Rev. Cytol., 2001, vol. 204, 1-48 **[0002]**
- **BUSSOLINO, F.** Trends Biochem. Sci., 1997, vol. 22, 251-256 **[0002]**

- Tumor Angiogenesis **FOLKMAN et al.** The Molecular Basis of Cancer W. B. Saunders 1995 0000 vol. 10, 206-32 [0004]
- **WEIDNER** New Eng. J. Med., 1991, vol. 324, 11-8 [0004]
- **O'REILLY et al.** Cell, 1994, vol. 79, 315-28 [0004]
- **O'REILLY et al.** Cell, 1997, vol. 88, 277-85 [0004]
- **TEISCHER et al.** Int. J. Cancer, 1994, vol. 57, 920-25 [0004]
- **KRUEGAR et al.** EMBO J., 1990, vol. 9, [0009]
- **ARDELT, A.A. et al.** Vascular Leak Syndromes Stroke, 2005, vol. 36, 337-341 [0074]
- **AUERBACH, R. et al.** Clin Chem, 2003, vol. 49, 32-40 [0083]
- **VAILHE, B. et al.** Lab Invest, 2001, vol. 81, 439-452 [0083]
- **SIMONS et al.** Clinical trials in coronary angiogenesis Circulation, 2000, vol. 102, 73-86 [0087]

Patentkrav

1. Forbindelse til anvendelse i behandling af vaskulær lækage-syndromer, hvilken forbindelse har formelen:



hvor R er en enhed valgt fra:

i) hydrogen;


10 ii) phenyl, 4-fluorphenyl, 2-hydroxyphenyl, 3-methylphenyl, 2-amino-4-fluorphenyl, 2-(N,N-diethylamino)phenyl, 2-cyanophenyl, 2,6-di-tert-butylphenyl, og 3-methoxyphenyl; og

15 iii) en heteroaryl-enhed valgt fra 1,2,3,4- tetrazol-1-yl, 1,2,3,4-tetrazol-5-yl, [1,2,3]triazol-4-yl, [1,2,3]triazol-5-yl, [1,2,4]triazol-4-yl, [1,2,4]triazol-5-yl, imidazol-2-yl, imidazol-4-yl, pyrrol-2-yl, pyrrol-3-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, [1,2,4]oxadiazol-3-yl, [1,2,4]oxadiazol-5-yl, [1,3,4]oxadiazol-2-yl, furan-2-yl, furan-3-yl, thiophen-2-yl, thiophen-3-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, [1,2,4]thiadiazol-3-yl, [1,2,4]thiadiazol-5-yl, og [1,3,4]thiadiazol-2-yl; hvor heteroaryl-

20 enheden kan være substitueret med en eller flere enheder valgt fra methyl, ethyl, n-propyl, iso-propyl, cyclopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, cyclopropylmethyl, methoxy, ethoxy, n-propoxy, iso-propoxy, cyclopropoxy, n-butoxy, sec-butoxy, iso-butoxy, tert-butoxy, fluor, chlor, fluormethyl, difluormethyl, og

25 trifluormethyl,

Z er en substitueret eller ikke-substitueret [1,3,4]thiadiazol-2-yl-enhed med formlen:



R¹ er valgt fra:

- 5 i) hydrogen;
- ii) ikke-substitueret C₁-C₆ lineær, forgrenet, eller cyklisk alkyl, eller substitueret C₁-C₆ lineær, forgrenet, eller cyklisk alkyl valgt fra hydroxymethyl, chlormethyl, trifluormethyl, aminomethyl, 1-chlorethyl, 2-hydroxyethyl, 1,2-difluorethyl, 2,2,2-trifluorethyl, 3-carboxypropyl, og 2,3-dihydroxycyclobutyl;
- 10 iii) ikke-substitueret C₆ eller C₁₀ aryl, eller substitueret C₆ eller C₁₀ aryl valgt fra 2-fluorphenyl, 3-fluorphenyl, 4-fluorphenyl, 2-chlorphenyl, 3-chlorphenyl, 4-chlorphenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-ethylphenyl, 3-ethylphenyl, 4-ethylphenyl, 2-isopropylphenyl, 3-isopropylphenyl, 4-isopropylphenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 2-nitrophenyl, 3-nitrophenyl, 4-nitrophenyl, 2-aminophenyl, 2-(N-methylamino)phenyl, 2-(N,N-dimethylamino)phenyl, 2-(N-ethylamino)phenyl, 2-(N,N-diethylamino)phenyl, 3-aminophenyl, 3-(N-methylamino)phenyl, 3-(N,N-dimethylamino)phenyl, 3-(N-ethylamino)phenyl, 3-(N,N-diethylamino)phenyl, 4-aminophenyl, 4-(N-methylamino)phenyl, 4-(N,N-dimethylamino)phenyl, 4-(N-ethylamino)phenyl, 4-(N,N-diethylamino)phenyl, naphthylen-1-yl, og naphthylen-2-yl;
- 15 iv) -OR⁴;
- 20 v) -C(O)OR⁵;
- vi) -COR⁶; eller
- 25 vii) -NR⁷C(O)OR⁸;

R^4 er hydrogen eller C_1 - C_6 lineær, forgrenet, eller cyklisk alkyl;

R^5 er C_1 - C_6 lineær eller forgrenet alkyl, eller benzyl;

R^6 er C_1 - C_6 lineær, forgrenet, eller cyklisk alkyl, eller phenyl;

R^7 er hydrogen eller methyl;

5 R^8 er C_1 - C_6 lineær eller forgrenet alkyl, eller benzyl;

L er en enhed med formel $-[C(R^{9a}R^{9b})]_y-$;


R^{9a} og R^{9b} er hver uafhængigt hydrogen, C_1 - C_6 lineær eller forgrenet alkyl, eller phenyl;

10 når L er en enhed med formlen $-CH_2-$, kan R^1 også vælges fra substitueret eller ikke-substitueret thiazol-4-yl, hvilke substitutioner er valgt fra methyl, ethyl, fluor, og chlor, og


indekset x er 0 eller 1; indekset y er fra 1 til 4; eller

et farmaceutisk acceptabelt salt deraf.

15 **2.** Forbindelsen til anvendelse ifølge krav 1, hvor R er valgt fra 1,2,3,4-tetrazolyl; [1,2,3]triazolyl; imidazolyl; pyrrolyl; oxazolyl; isoxazolyl; [1,2,4]-oxadiazolyl; [1,3,4]-oxadiazolyl; furanyl; thiophenyl; isothiazolyl; thiazolyl; [1,2,4]-thiadiazolyl; og [1,3,4]-thiadiazolyl; eller fra



20



- 3.** Forbindelsen til anvendelse ifølge krav 1, hvor R er phenyl eller thiophen-2-yl.
- 4.** Forbindelsen til anvendelse ifølge krav 1, hvor R¹ er valgt fra methyl, ethyl, n-propyl, iso-propyl, cyclopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, cyclobutyl, cyclopentyl, cyclohexyl, hydroxymethyl, chlormethyl, trifluormethyl, aminomethyl, 1-chlorethyl, 2-hydroxyethyl, 1,2-difluorethyl, 2,2,2-trifluorethyl, 3-carboxypropyl, 2,3-dihydroxycyclobutyl.
- 5.** Forbindelsen til anvendelse ifølge et hvilket som helst af kravene 1-4, hvor R¹ er valgt fra methyl, ethyl, n-propyl, iso-propyl, cyclopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, og cyclopropylmethyl.
- 6.** Forbindelsen til anvendelse ifølge et hvilket som helst af kravene 1-5, hvor L har formelen -CH₂-.
- 7.** Forbindelsen til anvendelse ifølge krav 6, hvor R¹ er valgt fra substitueret eller ikke-substitueret phenyl, naphthalen-1-yl, og thiazol-2-yl, hvilke substitutioner er valgt fra methyl, ethyl, fluor, og chlor.
- 8.** Forbindelsen til anvendelse ifølge krav 1, hvor forbindelserne er salte omfattende anioner valgt fra chlorid, bromid, iodid, sulfat, bisulfat, carbonat, bicarbonat, phosphat, format, acetat, propionat, butyrat, pyruvat, laktat, oxalat, malonat, maleat, succinat, tartrat, fumarat, og citrat eller kationer valgt fra natrium, lithium, kalium, calcium, magnesium, og bismut.
- 9.** Forbindelsen til anvendelse ifølge krav 1, hvor forbindelsen er valgt fra:
- (S)-4-(2-(5-Phenyl-1,3,4-thiadiazol-2-ylamino)-2-(2-phenylthiazol-4-yl)ethyl)-phenylsulfaminsyre;
- 4-((S)-2-(5-Propyl-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenylsulfaminsyre;

4-((S)-2-(5-Benzyl-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenylsulfaminsyre;

4-((S)-2-(5-(Naphthalen-1-ylmethyl)-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenylsulfaminsyre;

5 4-((S)-2-(5-((Methoxycarbonyl)methyl)-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenylsulfaminsyre; og

4-((S)-2-(5-((2-Methylthiazol-4-yl)methyl)-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenylsulfaminsyre.

10 **10.** Farmaceutisk sammensætning til anvendelse i behandling af vaskulær lækage-syndrom omfattende:

A) en eller flere forbindelser ifølge krav 1; og

B) en eller flere excipients eller bærere.